当前位置:首页 > 报告详情

Oneness-2026_JPM_Oneness_full_version-0115_final_en_unlocked.pdf

上传人: 明**** 编号:1069770 2026-01-17 34页 2.12MB

1、9:30-9:55 AM January 15th,2026(PST)Transforming Global Diabetes OutcomesFrom limb-saving DFU therapy to next-gen obesity innovationJ.P.Morgan Healthcare Conference 2026 2025 Oneness Biotech Co.,Ltd.All rights reserved.|This presentation contains forward looking statements.All statements other than s

2、tatements of historical facts included in thispresentation,including,without limitation,those regarding our financial position,business strategy,plans and objectives of managementfor future operations(including development plans and objectives relating to our products),are forward looking statements

3、.Such forwardlooking statements involve known and unknown risks,uncertainties and other factors which may cause our actual results,performanceor achievements to be materially different from any future results,performance or achievements expressed or implied by such forwardlooking statements.Such for

4、ward looking statements are based on numerous assumptions regarding our present and future businessstrategies and the environment in which we will operate in the future.The important factors that could cause our actual results,performance or achievements to differ materially from those in the forwar

5、d looking statements include,among others,risks associatedwith product discovery and development,uncertainties related to the outcome of clinical trials,slower than expected rates of patientrecruitment,unforeseen safety issues resulting from the administration of our products in patients,uncertainti

6、es related to productmanufacturing,the lack of market acceptance of our products,our inability to manage growth,the competitive environment in relation toour business area and markets,our inability to attract and retain suitably qualified personnel,the unenforceability or lack of protection ofour pa

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
1. **公司定位**:Oneness Biotech(TPEx: 4743)为全球代谢疾病领域开发First-in-Class/Best-in-Class创新产品,核心管线为糖尿病足溃疡(DFU)药物Fespixon®/Bonvadis®(ON101)及肥胖症siRNA药物SNS851。 2. **DFU疗法**: - 临床数据:ON101在RCT中显示16周愈合率60.7%(vs 标准护理35.1%),降低截肢风险80%;RWE中高感染风险患者截肢风险降低85%。 - 市场潜力:全球伤口护理市场超$300B,ON101目标市场$10B,已获70国市场准入。 3. **肥胖症创新**: - SNS851为肝脏靶向siRNA,临床前显示减重同时保留肌肉,与GLP-1联用可增强疗效70%、减少反弹70%。 - 机制优势:无GI副作用、避免肌肉流失,定位GLP-1后“维持疗法”,目标市场超$100B。 4. **商业化进展**: - DFU产品:美国510(k)获批,中国通过NRDL,欧盟CE Mark预计2026年。 - 生产能力:自有PIC/s GMP工厂,年产能2500万管(15g/管)。 5. **财务与ESG**: - 里程碑:2020年LEOPharma授权$5.3B,2024年CR Double Crane授权$3400万首付。 - ESG表现:入选S&P全球制药业ESG前10%、道琼斯可持续发展指数。
糖尿病足新疗法? 肥胖药有何突破? 生物科技如何创新?
客服
商务合作
小程序
服务号
折叠